Regulus Therapeutics reported $-7531000 in EBITDA for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Alnylam Pharmaceuticals ALNY:US USD -247440000 65.85M
AstraZeneca AZN:LN USD 3.6B 404M
Astrazeneca AZN:US USD 3.6B 404M
Biogen BIIB:US USD 992.8M 82.9M
Gilead Sciences GILD:US USD 2.7B 662M
GlaxoSmithKline GSK:LN GBP 1.6B 1.76B
Intercept Pharmaceuticals ICPT:US USD -10064000 808K
Intrexon XON:US USD -5899000 15.79M
Omeros OMER:US USD -50446000 13.2M
Regulus Therapeutics RGLS:US USD -7531000 387K
Sangamo Biosciences SGMO:US USD -51845000 8.99M
Takeda 4502:JP JPY 323.87B 51.6B
Vital Therapies VTL:US USD -20099000 491K
YTE INCY:US USD 134.94M 141.85M